Home > Publications database > Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. > print

001     143287
005     20240229112547.0
024 7 _ |a 10.1634/theoncologist.2018-0515
|2 doi
024 7 _ |a pmid:30926674
|2 pmid
024 7 _ |a 1083-7159
|2 ISSN
024 7 _ |a 1549-490X
|2 ISSN
024 7 _ |a 2159-8401
|2 ISSN
024 7 _ |a altmetric:69229683
|2 altmetric
037 _ _ |a DKFZ-2019-00885
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Thierauf, Julia
|b 0
245 _ _ |a Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma.
260 _ _ |a Hoboken, NJ
|c 2019
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1572427782_4666
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Adenoid cystic carcinoma (ACC) is an aggressive salivary gland malignancy without effective systemic therapies. Delineation of molecular profiles in ACC has led to an increased number of biomarker-stratified clinical trials; however, the clinical utility and U.S.-centric financial sustainability of integrated next-generation sequencing (NGS) in routine practice has, to our knowledge, not been assessed.In our practice, NGS genotyping was implemented at the discretion of the primary clinician. We combined NGS-based mutation and fusion detection, with MYB break-apart fluorescent in situ hybridization (FISH) and MYB immunohistochemistry. Utility was defined as the fraction of patients with tumors harboring alterations that are potentially amenable to targeted therapies. Financial sustainability was assessed using the fraction of global reimbursement.Among 181 consecutive ACC cases (2011-2018), prospective genotyping was performed in 11% (n = 20/181; n = 8 nonresectable). Testing identified 5/20 (25%) NOTCH1 aberrations, 6/20 (30%) MYB-NFIB fusions (all confirmed by FISH), and 2/20 (10%) MYBL1-NFIB fusions. Overall, these three alterations (MYB/MYBL1/NOTCH1) made up 65% of patients, and this subset had a more aggressive course with significantly shorter progression-free survival. In 75% (n = 6/8) of nonresectable patients, we detected potentially actionable alterations. Financial analysis of the global charges, including NGS codes, indicated 63% reimbursement, which is in line with national (U.S.-based) and international levels of reimbursement CONCLUSION: Prospective routine clinical genotyping in ACC can identify clinically relevant subsets of patients and is approaching financial sustainability. Demonstrating clinical utility and financial sustainability in an orphan disease (ACC) requires a multiyear and multidimensional program.Delineation of molecular profiles in adenoid cystic carcinoma (ACC) has been accomplished in the research setting; however, the ability to identify relevant patient subsets in clinical practice has not been assessed. This work presents an approach to perform integrated molecular genotyping of patients with ACC with nonresectable, recurrent, or systemic disease. It was determined that 75% of nonresectable patients harbor potentially actionable alterations and that 63% of charges are reimbursed. This report outlines that orphan diseases such as ACC require a multiyear, multidimensional program to demonstrate utility in clinical practice.
536 _ _ |a 311 - Signalling pathways, cell and tumor biology (POF3-311)
|0 G:(DE-HGF)POF3-311
|c POF3-311
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Ramamurthy, Nisha
|b 1
700 1 _ |a Jo, Vickie Y
|b 2
700 1 _ |a Robinson, Hayley
|b 3
700 1 _ |a Frazier, Ryan P
|b 4
700 1 _ |a Gonzalez, Jonathan
|b 5
700 1 _ |a Pacula, Maciej
|b 6
700 1 _ |a Dominguez Meneses, Enrique
|b 7
700 1 _ |a Nose, Vania
|b 8
700 1 _ |a Nardi, Valentina
|b 9
700 1 _ |a Dias-Santagata, Dora
|b 10
700 1 _ |a Le, Long P
|b 11
700 1 _ |a Lin, Derrick T
|b 12
700 1 _ |a Faquin, William C
|b 13
700 1 _ |a Wirth, Lori J
|b 14
700 1 _ |a Hess, Jochen
|0 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f
|b 15
|u dkfz
700 1 _ |a Iafrate, A John
|b 16
700 1 _ |a Lennerz, Jochen K
|b 17
773 _ _ |a 10.1634/theoncologist.2018-0515
|g p. theoncologist.2018-0515 -
|0 PERI:(DE-600)2023829-0
|n 10
|p 1356-1367
|t The oncologist
|v 24
|y 2019
|x 1549-490X
909 C O |o oai:inrepo02.dkfz.de:143287
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-311
|2 G:(DE-HGF)POF3-300
|v Signalling pathways, cell and tumor biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ONCOLOGIST : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ONCOLOGIST : 2017
920 1 _ |0 I:(DE-He78)A102-20160331
|k A102
|l Molekulare Grundlagen von HNO-Tumoren
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A102-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21